Evidence map›Paper›PMID 39829498›Full record

ArticleACS omega2025

Green Synthesis of Tetrahydropyrazino[2,1-a:5,4-a']diisoquinolines as SARS-CoV-2 Entry Inhibitors.

Sowndarya Palla, Srinivasa Rao Palla, Jia-Jin Liu, Tai-Ling Chao, Ting-Hui Lee, Veerababurao Kavala, I-Chen Liu, Lily Hui-Ching Wang, Sui-Yuan Chang, Ching-Fa Yao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sowndarya PallaDepartment of Chemistry, National Taiwan Normal University, Taipei 11677, Taiwan.
Srinivasa Rao PallaInstitute of Biochemical Sciences, National Taiwan University, Taipei 10617, Taiwan.
Jia-Jin LiuInstitute of Biochemical Sciences, National Taiwan University, Taipei 10617, Taiwan.
Tai-Ling ChaoDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei 10048, Taiwan.
Ting-Hui LeeDepartment of Life Science, National Tsing Hua University, Hsinchu 30013, Taiwan.
Veerababurao KavalaDepartment of Chemistry, National Taiwan Normal University, Taipei 11677, Taiwan.
I-Chen LiuInstitute of Biochemical Sciences, National Taiwan University, Taipei 10617, Taiwan.
Lily Hui-Ching WangInstitute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 30013, Taiwan.
Sui-Yuan ChangDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei 10048, Taiwan.ORCID https://orcid.org/0000-0002-6009-6724
Ching-Fa YaoDepartment of Chemistry, National Taiwan Normal University, Taipei 11677, Taiwan.ORCID https://orcid.org/0000-0002-8692-5156
Po-Huang LiangInstitute of Biological Chemistry, Academia Sinica, Taipei 11529, Taiwan.ORCID https://orcid.org/0000-0003-1207-5256

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A class of tetrahydropyrazino[2,1-a:5,4-a']diisoquinoline derivatives were synthesized under environmentally friendly conditions using water as the solvent. The 3-D structures of some synthesized compounds were determined by X-ray diffraction. Since naturally occurring isoquinoline alkaloids have significant antiviral activities against a wide range of viruses, including coronaviruses, the synthesized compounds were assayed for their inhibitory activities against SARS-CoV-2. Our results showed that the active compounds

Identifiers

PMID39829498
PMCPMC11740144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.